Do Yeun Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Do Yeun Cho has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jong Gwon Choi
Department of Oncology-Hematology, Konyang University Hospital, Daejeon, Republic of Korea
2 shared publications Dong Chul Lee
Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
1 shared publication- Jaeku Kang
Department of Pharmacology, College of Medicine, Konyang University, Daejeon, Korea
1 shared publication Seong-Lan Yu
Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Republic of Korea,
1 shared publication- Seung-Woo Baek
Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
1 shared publication
Latest Publications
- Open Access
- 31 March 2022
- Published by Springer Nature in Blood Research
- Vol. 57 (1) , 69-74
Myeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report
- 31 March 2022
- Published by Springer Nature in Blood Research
- Vol. 57 (1) , 69-74
Open AccessMyeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report
- Open Access
- 1 November 2018
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 6379-6389
Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
Purpose: The PI3K/AKT/mTOR pathway is frequently activated in various squamous cell carcinomas (SCCs). Although mTOR inhibitors are suggested as effective treatments in immunosuppressed patients with metastatic SCC, they are still not proven to be favorable in treating skin SCC patients not undergoing immunosuppressive therapy. Moreover, the exact mechanism of the mTOR signaling pathway in SCC has not yet been identified. In this study, we aimed to determine the genes associated with mTOR inhibitors in skin SCC. Materials and methods: The identification of cell viability according to concentration of everolimus and Western blot was done. To analyze the global gene expression profiles, A431 and HSC-1 cells were treated with dimethyl sulfoxide (DMSO) or 100 nM of everolimus for 72 hours. Furthermore, differentially expressed genes (DEGs) were identified using Affymetrix analysis. To identify the gene network associated with everolimus resistance in SCC cells, pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) tool. Results: The effects of cell death with respect to the mTOR inhibitor concentration were observed in the HSC-1 cell line; however, the mTOR inhibitor did not show effective cytotoxic activity in the A431 cell line. p-mTOR concentration also diminished with respect to everolimus concentrations in the HSC-1 cell line. Moreover, the microarray results showed that the MYC/CCND1/TP73/NUPR1/SBD/ERBB2/CDKN2B genes were related to mTOR inhibitor resistance. However, CCND1 gene overexpression was most closely related to mTOR inhibitor resistance. Conclusion: We identified mTOR inhibitor resistance genes, and our findings may help select therapeutic targets in skin SCC.
- 1 November 2018
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 6379-6389
Open AccessIdentification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
Purpose: The PI3K/AKT/mTOR pathway is frequently activated in various squamous cell carcinomas (SCCs). Although mTOR inhibitors are suggested as effective treatments in immunosuppressed patients with metastatic SCC, they are still not proven to be favorable in treating skin SCC patients not undergoing immunosuppressive therapy. Moreover, the exact mechanism of the mTOR signaling pathway in SCC has not yet been identified. In this study, we aimed to determine the genes associated with mTOR inhibitors in skin SCC. Materials and methods: The identification of cell viability according to concentration of everolimus and Western blot was done. To analyze the global gene expression profiles, A431 and HSC-1 cells were treated with dimethyl sulfoxide (DMSO) or 100 nM of everolimus for 72 hours. Furthermore, differentially expressed genes (DEGs) were identified using Affymetrix analysis. To identify the gene network associated with everolimus resistance in SCC cells, pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) tool. Results: The effects of cell death with respect to the mTOR inhibitor concentration were observed in the HSC-1 cell line; however, the mTOR inhibitor did not show effective cytotoxic activity in the A431 cell line. p-mTOR concentration also diminished with respect to everolimus concentrations in the HSC-1 cell line. Moreover, the microarray results showed that the MYC/CCND1/TP73/NUPR1/SBD/ERBB2/CDKN2B genes were related to mTOR inhibitor resistance. However, CCND1 gene overexpression was most closely related to mTOR inhibitor resistance. Conclusion: We identified mTOR inhibitor resistance genes, and our findings may help select therapeutic targets in skin SCC.